Prevalence of metabolic syndrome in early perioperative period after renal tranplantation
- Authors: Zagorodnikova N.V1, Rzhevskaya O.N1, Lazareva K.E1, Shmarina N.V1, Pinchuk A.V1
-
Affiliations:
- Issue: No 3 (2013)
- Pages: 17-19
- Section: Articles
- URL: https://journals.eco-vector.com/2075-3594/article/view/261765
- ID: 261765
Cite item
Open Access
Access granted
Abstract
Aim. Estimation of prevalence of metabolic syndrome in patients in early perioperative period after renal transplantation. Methods. 60 patients in early (30 days) perioperative period after renal transplantation were included into the study. All patients received standard triple immunosupressive therapy. Metabolic syndrome was diagnosed according to body mass index, glycemia, blood pressure, serum total cholesterol, triglycerides, HDL-, LDL- and VLDL-cholesterol levels, uricemia was also detertmined. Results. 26,7% of patients had excess body mass, 18,3% - obesity of I degree, 5,0% - obesity of II degree. Hyperglycemia was found in 25%, in 50% - dislipoproteinemia; 75% of patients had arterial hypertension, 40% - tendency for hyperuricemia. Majority of patients in early perioperative period after renal transplantation require correction of metabolic syndrome.
Full Text
About the authors
N. V Zagorodnikova
Email: zagorodnikova.n@mail.ru
O. N Rzhevskaya
K. E Lazareva
N. V Shmarina
A. V Pinchuk
References
- Шрайер Р.В. (ред.); перевод с англ. под ред. Н.А. Мухина. Руководство по нефрологии. М., 2009; 365 с.
- Данович Г.М. (ред.); перевод с англ. под ред. Я.Г. Мойсюка. Руководство по трансплантации почки 3-е изд. Тверь, 2004; 472 с.
- Roodnat J.I., Mulder P.G., Zietse R. et al. Cholesterol as an independent predictor of outcome after renal transplantation. Transplantation. 2000; 69: 1704-1710.
- Tutone V.K., Mark P.B., Stewart G.A. et al. Hypertension, antihypertensive agents and outcomes following renal transplantation. Clin Transplant. 2005; 19: 181-192.
- Kasiske B.L., Snyder J.J., Gilbertson D., Matas A.J. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant. 2003; 3: 178-185.
- Fellström B., Holdaas H., Jardine A.G. et al; Assessment of Lescol in Renal Transplantation Study Investigators. Risk factors for reaching renal endpoints in the Assessment of Lescol in Renal Transplantation (ALERT) trial. Transplantation. 2005; 79: 205-212.
- Gore J.L., Pham P.T., Danovitch G.M. et al. Obesity and outcome following renal transplantation. Am J Transplant. 2006; 6: 357-363.
- Elahi T., Akhtar F., Ahmed E., Naqvi R. Prevalence of metabolic syndrome in renal transplant recipients-- a single centre experience. 2009; 59(8): 533-536.
- Кононенко И.В., Суркова Е.В., Анциферов М.Б. Метаболический синдром с позиций эндокринолога: что мы знаем и что уже можем сделать. Проблемы эндокринологии. 1999; 2: 36-41.
- Villegas R., Perry I.J., Greagh D. Prevalence of metabolic syndrome in middle-aged men and women. Diabetes Care. 2003; 26(11): 3198-3199.
Supplementary files
